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The newly strengthened 
Competition Commission 
says it will probably 
begin its long-awaited, 
robust probe into South 
Africa’s increasingly unaffordable private 
healthcare market towards the end of this 
year, with final recommendations and 
findings due out in late 2015.
This comes after President Jacob 
Zuma announced in early March that 
the commission would be empowered to 
conduct formal market inquiries, with 
powers of subpoena and wide terms of 
reference. Taking effect from 1 April, these 
powers raise the bar on the commission’s 
previous probes. For example, in 2008, 
the Competition Commission completed 
a market enquiry into the banking sector, 
relying on its general powers (i.e. without 
the new investigative powers), and 
depending entirely on companies’ voluntary 
participation. While this had some impact 
on bank charges, it did not impact hugely 
on the way banks do business. In terms of 
the legislative amendment, the Commission 
can now issue summons to compel any 
person to appear before it or elicit any 
evidence which it believes may have a 
bearing on its proceedings. Failure to 
appear or to answer fully or truthfully 
during an inquiry can now constitute an 
offence, with heavy penalties. 
Trudie Makhaya, manager for stakeholder 
relations at the commission, told Izindaba 
that engagement with stakeholders (which 
began in November last year) would continue 
over the next three months, and that 
adjustments for the amended and enhanced 
new powers are ‘top of mind’. By July a final 
draft of the full terms of reference should be 
ready for gazetting, enabling the commission 
to begin hacking into the private healthcare 
labyrinth by, at the latest, 2014. 
‘It’s all geared towards understanding the 
market and its distortions in a holistic fashion 
– to understand where it’s failing – and then 
making recommendations to policy makers 
and regulators,’ she said. ‘We’ll present our 
findings to the Minister [of Health], who’ll 
present them to cabinet.’ 
Asked whether fines and other penalties 
against individual or collective sector players 
might result, Makhaya said this could be a 
byproduct of the wider investigation, which 
was aimed at ‘bigger competition policy 
problems’. ‘If we suspect price-fixing we can 
open a new probe and run with it [via the 
Competition Tribunal], imposing penalties 
– but that’s not our primary purpose,’ she 
emphasised. A market inquiry is a formal 
probe into the general state of competition 
in a market for particular goods or services, 
without necessarily referring to the conduct 
or activities of any particular corporate 
entity or firm.
Consensus pricing elusive
There have been repeated and urgent calls 
– from the Board of Healthcare Funders 
(BHF), doctor groupings and patient 
organisations – for a mutually agreed-upon 
forum that can set fair prices for medical 
services. At present it’s a ‘free-for-all’, with 
some specialists charging up to 500% of 
medical aid prices and patients coughing 
up the payment shortfall, in addition to 
their ever-rising monthly medical aid 
subscriptions. It’s a ‘zero-sum game’ with 
each stakeholder operating at the expense of 
the other, and the patient all but forgotten 
in the mix. 
As medical inflation soars, medical aids 
blame collusion between specialists and 
private hospitals (via perverse incentives 
such as inappropriate use of lucrative hi-tech 
equipment, general over-servicing and free 
or very low-rental office space), as well as 
collusion between patients and doctors to 
abuse hospital plans. Specialists point to 
almost intolerable workloads induced by 
serious shortages in their numbers, rampant 
brokerage and administration and managed-
care costs in medical aids, plus soaring 
litigation insurance costs. Last year Discovery 
Health Medical Scheme members called for 
an independent review of the R3.2 billion 
administration and managed care fee paid to 
the scheme’s administrator, Discovery Health, 
during the 2011 financial year.
Medical schemes argue that they are unable 
to act in the best interests of their members 
due to their lack of bargaining power relative 
to the powerful hospital groups. This 
followed a Competition Commission ruling 
in 2005 (aimed at preventing collective price 
setting without any regulatory oversight), 
which stopped price negotiations between 
the BHF, Hospitals Association of South 
Africa (HASA) and the South African 
Medical Association (SAMA). 
After this, differences between what 
healthcare providers charge and what 
medical schemes pay widened. Schemes cited 
an inability to keep paying higher amounts 
to providers, while providers claimed 
escalating costs were forcing them to charge 
more. The Competition Commission now 
holds that a regulatory vacuum arose after 
the Health Department’s tariff guidelines 
(aka the Reference Price List (RPL)) were 
struck down by the Gauteng High Court in 
2010, citing insufficient consultation and 
research. The commission argues that this 
needs to be addressed.
 Hospital groups 
‘dominant’
The hospital market is dominated by 
Netcare, Life Healthcare and Medi-Clinic, 
who collectively hold about 80% of the 
market. Independent hospitals, mostly 
represented through the National Hospital 
Network (NHN), make up the remainder, 
but market concentration is increasing as 
the three large hospital groups gradually 
acquire independent hospitals. Hospitals 
are not subject to price regulation (aside 
from the regulations which apply to the 
pricing of pharmaceutical products). In 
several previous healthcare hearings before 
the Competition Tribunal, the hospital 
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groups have denied the link between the 
gradual, systematic increase in private 
hospital concentration and the rising costs 
of healthcare.[1]
The Health Professions Council of South 
Africa (HPCSA) is now ‘gun shy’ about 
publishing its guideline tariffs for doctors and 
dentists, after these two groups threatened 
legal action in August last year. They argued 
that the HPCSA’s rates were too low, took no 
account of practitioners’ costs, and omitted 
numerous new procedures and practices. 
Since the RPL was struck down, calls 
to reverse the Competition Commission’s 
rulings, which put a stop to negotiations 
over healthcare tariffs, have become 
louder and were repeated at several 
parliamentary hearings. At the hearings, 
medical practitioners and medical schemes 
advocated a forum that can set fair prices for 
medical services. 
The health department expects that 
policies flowing from the commission’s 
market inquiry will be less susceptible to 
legal challenges from healthcare providers. 
However, it emphasises that it will continue 
to do all it can to ensure an interim pricing 
authority as soon as possible – without 
awaiting the Commission’s findings in 2015.
High road or low road?
A recent on-line commentary by a leading 
South African law firm, Werksmans 
Attorneys, strongly advises healthcare 
companies to ‘proactively’ consider their 
business interactions and agreements 
(especially those concerning price-setting 
mechanisms, information exchanges and 
interactions with competitors), well before 
the Commission reveals the full scope of its 
inquiry – in their own best interests. With 
the accelerating implementation of National 
Health Insurance, any further escalation in 
private healthcare costs will put additional 
and hugely unwelcome strain on the already 
overburdened public healthcare sector – 
winning its private counterpart few political 
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In terms of the legislative 
amendment, the Commission can 
now issue summons to compel 
any person to appear before it 
or elicit any evidence which it 
believes may have a bearing on 
its proceedings.
